Science

Vivek Subbiah: Exploring the role of ctDNA Clearance as a Predictive Biomarker in Solid Tumors

Vivek Subbiah/LinkedIn

Apr 8, 2025, 15:46

Vivek Subbiah: Exploring the role of ctDNA Clearance as a Predictive Biomarker in Solid Tumors

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a LinkedIn post about recent paper he and his colleagues authored:

“New paper alert! Pleased to share our paper.

A systematic review and meta-analysis exploring the role of “Circulating tumor DNA (ctDNA) clearance as a predictive biomarker for solid tumors treated with neoadjuvant immune-checkpoint inhibitors.”

Key takeaways:

1. Lack of ctDNA clearance may indicate patients unlikely to achieve pathologic complete response
2. However, the predictive power is limited by low specificity.

Kudos to the research team led by Giuseppe Curigliano and an amazing co-author team.

Read the full paper here.”

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Authors: C. Valenza, Vivek Subbiah, Giuseppe Curigliano et al.

Vivek Subbiah

A.H. Partridge C. Cremolini C. Valenza cancer D. Gritsch Dario Trapani E.F. Saldanha F. Conforti Giuseppe Curigliano H. Ortiz H.A. Parsons J. Mateo OncoDaily Oncology P De Placido S. Peters Vivek Subbiah Y. Gong

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers

Top 5 AI Tools for Radiation Oncologists: What Clinicians Need to Know